UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function

The Journal of clinical investigation, 2018-04, Vol.128 (4), p.1458-1470

2018

Volltextzugriff (PDF)

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

Molecular cancer therapeutics, 2015-04, Vol.14 (4), p.931-940

2015

Volltextzugriff (PDF)

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2

Bioorganic & medicinal chemistry letters, 2016-06, Vol.26 (12), p.2779-2783

2016

Volltextzugriff (PDF)

CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice

Molecular metabolism (Germany), 2019-02, Vol.20, p.89-101

2019

Volltextzugriff (PDF)

TOP-156 SRT-015: Novel therapeutic for cholestatic liver diseases

Journal of hepatology, 2024-06, Vol.80, p.S292-S292

2024

Volltextzugriff (PDF)

Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1

Journal of hepatology, 2023-06, Vol.78, p.S829

2023

Volltextzugriff (PDF)

FRI-528 - Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1

Journal of hepatology, 2023-06, Vol.78, p.S829-S829

2023

Volltextzugriff (PDF)

Abstract 13724: Development of VS-041 as a Precision Medicine Targeting Cardiac-Relevant Matrix Metalloproteases (MMPs) in Heart Failure With Preserved Ejection Fraction (HFpEF)

Circulation (New York, N.Y.), 2022-11, Vol.146 (Suppl_1)

2022

Volltextzugriff (PDF)

Stability of Cytotoxic Luteinizing Hormone-Releasing Hormone Conjugate (AN-152) Containing Doxorubicin 14-O-Hemiglutarate in Mouse and Human Serum in vitro: Implications for the Design of Preclinical Studies

Proceedings of the National Academy of Sciences - PNAS, 2000-01, Vol.97 (2), p.829-834

2000

Volltextzugriff (PDF)

FRI-397 - SRT-015, best-in-class apoptosis signal-regulating kinase 1 inhibitor, demonstrates preclinical efficacy in acute models of liver injury

Journal of hepatology, 2023-06, Vol.78, p.S139-S139

2023

Volltextzugriff (PDF)

SRT-015, best-in-class apoptosis signal-regulating kinase 1 inhibitor, demonstrates preclinical efficacy in acute models of liver injury

Journal of hepatology, 2023-06, Vol.78, p.S139

2023

Volltextzugriff (PDF)

Human Renal Cell Carcinoma Expresses Distinct Binding Sites for Growth Hormone-Releasing Hormone

Proceedings of the National Academy of Sciences - PNAS, 2000-09, Vol.97 (19), p.10555-10560

2000

Volltextzugriff (PDF)

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes

The Journal of biological chemistry, 2019-06, Vol.294 (24), p.9567-9575

2019

Volltextzugriff (PDF)

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

The Journal of pharmacology and experimental therapeutics, 2019-11, Vol.371 (2), p.299-308

2019

Volltextzugriff (PDF)

Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ

Bioorganic & medicinal chemistry letters, 2015-01, Vol.25 (2), p.372-377

2015

Volltextzugriff (PDF)

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 1

Bioorganic & medicinal chemistry letters, 2016-06, Vol.26 (12), p.2774-2778

2016

Volltextzugriff (PDF)

Hypothalamic Hormones and Cancer

Frontiers in neuroendocrinology, 2001-10, Vol.22 (4), p.248-291

2001

Volltextzugriff (PDF)

Time-dependent inhibition of PHD2

Bioscience reports, 2017-06, Vol.37 (3)

2017

Volltextzugriff (PDF)

Discovery of Highly Potent Liver X Receptor β Agonists

ACS medicinal chemistry letters, 2016-12, Vol.7 (12), p.1207-1212

2016

Volltextzugriff (PDF)

Discovery and Characterization of an Inhibitor of Glucosylceramide Synthase

Journal of medicinal chemistry, 2012-05, Vol.55 (9), p.4322-4335

2012

Volltextzugriff (PDF)

Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II

Cancer, 2002-10, Vol.95 (8), p.1735-1745

2002

Volltextzugriff (PDF)

Peptide analogs in the therapy of prostate cancer

The Prostate, 2000-10, Vol.45 (2), p.158-166

2000

Volltextzugriff (PDF)

in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215

International journal of cancer, 2000-11, Vol.88 (4), p.652-657

2000

Volltextzugriff (PDF)

Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238

Cancer research (Chicago, Ill.), 1999-04, Vol.59 (8), p.1947-1953

1999

Volltextzugriff (PDF)

Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa

European journal of endocrinology, 1995-02, Vol.132 (2), p.147-151

1995

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(30)
Animals
(28)
Humans
(27)
Mice
(24)
Male
(21)
Biological And Medical Sciences
(18)
Mice, Nude
(17)
Medical Sciences
(16)
Tumor Cells, Cultured
(15)
Antineoplastic Agents
(11)
Chemotherapy
(11)
Pharmacology. Drug Treatments
(11)
Doxorubicin - Analogs & Derivatives
(10)
Endocrinology & Metabolism
(10)
Oncology
(10)
Prostatic Neoplasms - Drug Therapy
(9)
Prostatic Neoplasms - Pathology
(9)
Dose-Response Relationship, Drug
(8)
Pharmacology & Pharmacy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

10 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2

CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice

TOP-156 SRT-015: Novel therapeutic for cholestatic liver diseases

Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1

FRI-528 - Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1

Abstract 13724: Development of VS-041 as a Precision Medicine Targeting Cardiac-Relevant Matrix Metalloproteases (MMPs) in Heart Failure With Preserved Ejection Fraction (HFpEF)

Stability of Cytotoxic Luteinizing Hormone-Releasing Hormone Conjugate (AN-152) Containing Doxorubicin 14-O-Hemiglutarate in Mouse and Human Serum in vitro: Implications for the Design of Preclinical Studies

FRI-397 - SRT-015, best-in-class apoptosis signal-regulating kinase 1 inhibitor, demonstrates preclinical efficacy in acute models of liver injury

SRT-015, best-in-class apoptosis signal-regulating kinase 1 inhibitor, demonstrates preclinical efficacy in acute models of liver injury

Human Renal Cell Carcinoma Expresses Distinct Binding Sites for Growth Hormone-Releasing Hormone

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 1

Hypothalamic Hormones and Cancer

Time-dependent inhibition of PHD2

Discovery of Highly Potent Liver X Receptor β Agonists

Discovery and Characterization of an Inhibitor of Glucosylceramide Synthase

Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II

Peptide analogs in the therapy of prostate cancer

in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215

Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238

Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa

Suchergebnisse filtern